company? Let’s change
Don't see your company?Create a company profile
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions to partner with our customers in helping them reach their goals and accelerate their projects at our cGMP-compliant facilities in the US, Europe and Japan, as well as to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Visit www.agcbio.com to learn more.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, Nautilus (Nasdaq: NAUT) set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. We specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research. As a company, we value technological and scientific excellence and are constantly pushing the envelope.
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
Viome is on a mission to prevent and reverse chronic diseases. Viome is a high-growth biotech startup that applies AI and machine learning to biological data – e.g., microbiome, transcriptome and metabolome data – to provide direct-to-consumer personalized dietary and lifestyle recommendations for healthier living. We are a small, fast-growing, interdisciplinary team of passionate experts in biochemistry, microbiology, medicine, artificial intelligence, and machine learning with a shared mission to make illness optional.
Vektor Medical, Inc is the developer of the world’s first technology to rapidly map arrhythmias anywhere in the heart using only 12-lead ECG data. The company’s smart, simple, and non-invasive cardiac arrhythmia mapping platform aims to improve first-pass ablation success, lower risks from invasive mapping and reduce procedure times.
Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
We consider all aspects of the design process to create the perfect space for our clients. The success of a space starts with thorough planning. Our mission is to design functional and beautiful spaces. Our initial planning encompasses each step of the process (concept design, schematic design, and design development) to arrive at the perfect point in our construction documents. 300 Aspen Airport Business Center, Unit B, Aspen, CO 81611 phone 970-544-5119
Lightspeed Microscopy Inc. reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology. Lightspeed, spun-out of the University of Washington and co-founded by Nick Reder in 2018, is based in Seattle, WA.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. Variant Bio is a Seattle-based biotech company entering a rapid growth stage having recently closed a $100mm+ Series B. The company was started because we believe that human genetics has the power to transform drug development. We are working towards developing therapies to improve global health by studying the genes of people who are outliers for medically relevant traits. To facilitate this, we have built proprietary genomics and phenotyping platforms that allow us to dramatically reduce the cost of genomic studies and identify genetically-validated targets for therapeutic development. All of our studies are co-designed with local partners: community groups, academics, and hospitals around the world, and we built Variant Bio from the ground up with ethics at its foundation. We recognize the contribution of our partners through an industry leading benefit-sharing program that dedicates 4% of our revenue and equity value to support local healthcare, sustainable development, education, research, and capacity-building initiatives. Variant Bio is an equal opportunity employer that guarantees a work environment that respects and values diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, sex, gender, gender expression, sexual orientation, age, marital status, veteran status, or disability status.